HOUSTON, April 9, 2019 /PRNewswire/ -- Moleculin
Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a
clinical stage pharmaceutical company with a broad portfolio of
drug candidates targeting highly resistant tumors, today announced
it has successfully expanded the clinical supply of Annamycin for
its on-going clinical trials via BSP Pharmaceuticals S.p.A.
(www.bsppharmaceuticals.com) in Latina, Italy.
"Securing production supply for a liposomal anthracycline like
Annamycin is no trivial matter, which is why we partnered last year
with a quality supplier like BSP, who will be able to supply
Annamycin in commercial quantities going forward," commented
Walter Klemp, Moleculin's Chairman
and CEO. "They have worked diligently to establish production
capability and are now supplying our Annamycin drug for our
clinical trials in the U.S. and the EU. We believe having a
partnership with a pharmaceutical manufacturer the caliber of BSP
mitigates our development risk and better positions us to further
advance the clinical development of Annamycin as we work to develop
effective solutions for the treatment of acute myeloid
leukemia."
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical
company focused on the development of oncology drug candidates, all
of which are based on discoveries made at M.D. Anderson Cancer
Center. The Company's clinical stage drugs are Annamycin, an
anthracycline designed to avoid multidrug resistance mechanisms
with little to no cardiotoxicity being studied for the treatment of
relapsed or refractory acute myeloid leukemia, more commonly
referred to as AML, and WP1066, an immuno-stimulating STAT3
inhibitor targeting brain tumors, pancreatic cancer and AML.
Moleculin Biotech is also engaged in preclinical development of
additional drug candidates, including additional STAT3 inhibitors
and compounds targeting the metabolism of tumors.
For more information about the Company, please visit
http://www.moleculin.com.
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of Moleculin to
successfully recruit sufficient patients to complete this clinical
trial and that ability of WP1220 to show safety and efficacy in
patients. Although Moleculin Biotech believes that the expectations
reflected in such forward-looking statements are reasonable as of
the date made, expectations may prove to have been materially
different from the results expressed or implied by such
forward-looking statements. Moleculin Biotech has attempted to
identify forward-looking statements by terminology including
''believes,'' ''estimates,'' ''anticipates,'' ''expects,''
''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,''
''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. These statements are
only predictions and involve known and unknown risks,
uncertainties, and other factors, including those discussed under
Item 1A. "Risk Factors" in our most recently filed Form 10-K filed
with the Securities and Exchange Commission ("SEC") and updated
from time to time in our Form 10-Q filings and in our other public
filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. We undertake
no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
Contacts
Joe Dorame,
Robert Blum or Joe Diaz
Lytham Partners, LLC
602-889-9700
mbrx@lythampartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/moleculin-announces-successful-expansion-of-its-leukemia-drug-program-300826533.html
SOURCE Moleculin Biotech, Inc.